

The Danish Collaborative Bacteraemia Network (DACOBAN) database

Kim Oren Gradel^{1,2}
 Henrik Carl Schønheyder^{3,4}
 Magnus Arpi⁵
 Jenny Dahl Knudsen⁶
 Christian Østergaard⁶
 Mette Søgaard⁷

For the Danish Collaborative Bacteraemia Network (DACOBAN)

¹Center for Clinical Epidemiology, Odense University Hospital, ²Research Unit of Clinical Epidemiology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; ³Department of Clinical Microbiology, Aalborg University Hospital, ⁴Department of Clinical Medicine, Aalborg University, Aalborg, ⁵Department of Clinical Microbiology, Herlev Hospital, Copenhagen University Hospital, Herlev, ⁶Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen University Hospital, Hvidovre, ⁷Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark

Correspondence: Kim Oren Gradel
 Center for Clinical Epidemiology, Odense University Hospital, Entrance 101, 4th floor, 29 Sønder Boulevard, Odense 5000, Denmark
 Tel +45 21 158 085
 Fax +45 65 917 264
 Email kim.gradel@rsyd.dk

Abstract: The Danish Collaborative Bacteraemia Network (DACOBAN) research database includes microbiological data obtained from positive blood cultures from a geographically and demographically well-defined population serviced by three clinical microbiology departments (1.7 million residents, 32% of the Danish population). The database also includes data on comorbidity from the Danish National Patient Registry, vital status from the Danish Civil Registration System, and clinical data on 31% of nonselected records in the database. Use of the unique civil registration number given to all Danish residents enables linkage to additional registries for specific research projects. The DACOBAN database is continuously updated, and it currently comprises 39,292 patients with 49,951 bacteremic episodes from 2000 through 2011. The database is part of an international network of population-based bacteremia registries from five developed countries on three continents. The main purpose of the DACOBAN database is to study surveillance, risk, and prognosis. Sex- and age-specific data on background populations enables the computation of incidence rates. In addition, the high number of patients facilitates studies of rare microorganisms. Thus far, studies on *Staphylococcus aureus*, enterococci, computer algorithms for the classification of bacteremic episodes, and prognosis and risk in relation to socioeconomic factors have been published.

Keywords: bacteremia, database, positive blood cultures, population-based

Introduction

Bacteremia is a serious condition, with a 30-day mortality of 15%–30% and ranked among the top-seven causes of death in developed countries.¹ The term “bacteremia” also covers fungemia, and is defined as the presence of bacteria or fungi in the bloodstream associated with clinical symptoms, distinguishing it from blood contamination.^{2,3} In practical terms, bacteremia is based on the detection of bacteria or fungi in blood cultures (BCs) ordered on suspicion of a possible bloodstream infection in an ill patient. The distinction between bacteremia and blood contamination requires due consideration. However, the most effective means of capturing all data is the electronic recording of bacteria and fungi in BCs, as performed by clinical microbiological laboratories.²

The Danish Collaborative Bacteraemia Network (DACOBAN) database is a research database compiled from administrative data. The main purpose of the database is to provide Danish population-based bacteremia data for studies related to surveillance, risk, and prognosis. DACOBAN covers 32% of the Danish population, and is part of a multinational bacteremia collaborative network that incorporates bacteremic data from all of Finland, as well as geographically and demographically well-defined regions in Canada, Australia, and Sweden.^{4,5}

Compilation of the study database

Linkage between data sources

All Danish residents have a unique personal identification number (the civil registration number) used in all administrative registries, which enables their linkage.⁶ Date of birth and sex are incorporated into this number.

Core data set

The core data set consists of microbiological data on all positive BCs from the clinical microbiology departments at the three hospitals in Aalborg, Herlev, and Hvidovre (Table 1), which use the same laboratory information system (ADBakt; Autonik, Sködinge, Sweden). The data are derived from patients with a civil registration number (ie, Danish residents), which comprise 99.5% of all positive BCs. BCs are rarely ordered by physicians outside the hospital setting, but if they are, they are normally collected in the outpatient area at the nearest hospital and are thereby captured by the DACOBAN database. All departments use automated BC systems (Bactec™ [BD, Franklin Lakes, NJ, USA] or BacT/Alert® [bioMérieux, Marcy l'Etoile, France]) and conventional identification methods,⁷ possibly supplemented with automatic methods, such as Vitek® 2 (bioMérieux) or MALDI-TOF (Bruker, Bremen, Germany).

Linkage between the core data set and other registries

The Danish National Patient Registry (DNPR) includes all hospital diagnoses and surgical procedures from 1977 onward.⁸ The DNPR comprises inpatients from the whole

period, and outpatients and emergency visits since 1995. As all data are received electronically from the hospitals' patient administrative systems, the DNPR is updated shortly after discharge of the patient. For patients in the DACOBAN database, we have access to their hospital history since 1977, including information on number and length of admissions, minor and major surgical procedures, and specific disease entities.

The Danish Civil Registration System, which was implemented in 1968, is updated daily.⁶ This registry contains information on the patients' vital status, including date of death, disappearance, or emigration if relevant. In addition to linkage to other health registries, physicians at the three clinical microbiology departments prospectively record additional clinical variables for the DACOBAN, as outlined in the following sections.

Survey frequency

The DACOBAN database receives core data when physicians at the three clinical microbiology departments validate the laboratory data. Currently, the DACOBAN database includes all of 2011, and future updates are expected for full years 6–12 months after their expiry, from the laboratories, the DNPR, and the Danish Civil Registration System. The latest date of the patients' vital status derived from the Danish Civil Registration System⁶ is September 27, 2012.

Data-resource area and population coverage

The Danish tax-funded welfare system provides free access to health care by general practitioners and at public hospitals.

Table 1 Hospital and population data

DCM at	Hospitals ^a	One blood-culture set	Blood-culture system	Area (years)	Population (year) ^b
Aalborg Hospital	4 (1,347) ^c	Children: 1×10 mL Adults: 3×10 mL	BacT/Alert	County of North Jutland (2000–2006) North Denmark Region (2007–2011)	494,153 (2000) 580,293 (2011) ^d
Herlev Hospital	3 (1,587)	Children: 1×10 mL Adults: 2×10 mL	Bactec	Copenhagen County (2000–2006) Capital Region, corresponding to the former Copenhagen County (2007–2011)	613,444 (2000) 648,449 (2011) ^e
Hvidovre Hospital	5 (1,639)	Children: 1×10 mL Adults: 2×10 mL	BacT/Alert	Copenhagen municipality, Frederiksberg municipality, Bornholm regional municipality (2000–2006) Capital Region, corresponding to the former Copenhagen, Frederiksberg, and Bornholm municipalities (2007–2011)	630,462 (2000) 690,146 (2011)

Notes: ^aHospitals submitting blood cultures to the DCM; ^bcompiled from <http://www.statistikbanken.dk> (accessed August 5, 2013); ^cnumber of hospitals in 2011 (beds in the hospitals in 2009, compiled from <http://www.ssi.dk/Sundhedsdataogit/Dataformidling/Sundhedsdata/Sengepladser.aspx> [accessed September 4, 2013]); ^dservices from DCM, Aalborg Hospital to Thy-Mors Hospital (catchment population 45,000, 146 beds) took effect in 2011; ^ethree municipalities (Søllerød, Værløse, Ledøje-Smørum) in Frederiksberg County before 2007 were merged with municipalities from Copenhagen County in 2007. The 61,350 inhabitants of these municipalities (in 2006, data unavailable thereafter) were subtracted from the number of inhabitants in the Capital Region (excluding Copenhagen, Frederiksberg, and Bornholm municipalities). Manufacturer details are as follows: Bactec™ (BD, Franklin Lakes, NJ, USA), BacT/Alert® (bioMérieux, Marcy l'Etoile, France).

Abbreviation: DCM, Department of Clinical Microbiology.

Only 1% of hospital beds are in the private sector, and these are used solely for elective admissions. The public health service has a regional structure, which is subject to change, with the most recent change occurring in 2007. Until 2007, Denmark was divided into 14 counties, which were reorganized into five regions. This reorganization had very little impact on the background population of the DACOBAN database, and almost none for the present Capital Region, but it led to a 17% increase in the population when North Jutland County was reorganized into the North Denmark Region.⁹ Population data can be obtained from Statistics Denmark (<http://www.statbank.dk>, in English) for the calculation of incidence data.

The admission of all acutely ill patients to the nearest public hospital in their region of residence and the submission of all of the hospitals' BCs to the three clinical microbiology departments prompts population-based coverage of the DACOBAN database.¹⁰ However, the main Danish referral hospital (Rigshospitalet), which is situated in Copenhagen, has bacteremia episodes that are not captured by the DACOBAN database. We estimate that approximately 16% of bacteremic episodes among residents in the Capital Region occur at the Rigshospitalet, with a preponderance of nosocomial episodes among 0- to 40-year-old patients occurring in highly specialized wards (such as oncology, hematology, or nephrology) in this hospital (unpublished data). We plan to include microbiological data from Rigshospitalet in the DACOBAN database after taking its different laboratory information system (MADS [<http://www.madsonline.dk>]) into account.

Therefore, the DACOBAN database covers all positive BCs from the North Denmark Region and approximately 84% of positive BCs from the Capital Region; given the distribution of BCs between these two regions in the DACOBAN database (data not shown), coverage is estimated to be 88%. These two geographically and demographically well-defined administrative regions have a background population of approximately 1.7 million (32% of Denmark's population, Table 1).⁵ Currently, the data cover the 12-year period from January 1, 2000 through December 31, 2011.

In future, DACOBAN data will include positive BCs from additional municipalities in the Capital Region (background population approximately 0.3 million), which were incorporated into the Herlev catchment area in May 2013.

Measures

Analytical units

A BC set comprises a number of BC bottles drawn simultaneously from the patient (Table 1), and is the unit used in the literature to derive bacteremic episodes.¹¹ We cannot derive

BC sets from the DACOBAN database,¹² because each clinical microbiology department uses its own laboratory-specimen numbering. Therefore, we have to use dates instead of BC sets, which is a reasonable assumption because BC bottles drawn on the same date presumably represent the same bacteremic episode. Using dates, we apply commonly used algorithms for contamination episodes based on the likelihood of a given microbial species to originate from the skin flora versus the bloodstream,¹¹ characterizing the remaining BCs as representing true bacteremia. Therefore, we compute bacteremic episodes on the basis of consecutive dates of positive BCs.^{3,12}

Patients and bacteremic episodes

Currently, the DACOBAN database includes 39,292 patients with 49,951 bacteremic episodes. The age-related incidences (Figure 1) and other main characteristics (Table 2) do not differ materially from bacteremic patients in other population-based studies.^{13,14}

Main categories and variables

We divided the DACOBAN database into variables related to basic characteristics, microbiology, comorbidity, vital status, and physicians' supplementary variables (Table 3).

Basic characteristics

The best-estimate date represented the baseline date of the bacteremic episode. The start of the bacteremic episode was defined as the date of drawing the BC. However, the date of the draw was missing in 4,228 bacteremic episodes (8.5%). We substituted the date of the draw with the date of BC receipt in clinical microbiology departments for these episodes. For the remaining 45,723 bacteremic episodes, 98.4% had ≤ 1 day between the draw date and the receipt date. From 2013, the electronic requisition of all BCs in the Capital Region precluded missing draw dates. Bacteremic episodes and the acquisition of bacteremia were computer-derived¹² on the basis of generally accepted criteria.^{11,15,16}

Microbiological data

Detection systems (eg, different media or numbers of bottles) differ between clinical microbiology departments (Table 1) and over time within the same department.¹⁷ However, the main caveat relates to data on antibiotic resistance. The three departments have not coordinated on procedures, minimum inhibitory concentration values, or standard panels, yet all three departments participate in the same external quality-assessment schemes, primarily the UK National




Figure 1 Age-related bacteremic episodes per 10,000 person years among 49,951 bacteremic episodes, 2000–2011. Each column covers 1 year. Age 101–106 years (n=21) merged.

External Quality Assessment Service (<http://www.ukneqas-micro.org.uk>). Work is ongoing to evaluate past methods for antibiotic resistance that apply to all departments, but before this is implemented, generations of these data may differ between the departments, and caution in their interpretation is warranted.

Comorbidity

Comorbidity was assessed on the basis of the Charlson Comorbidity Index, in which 19 major disease categories (eg, malignancy, cardiovascular diseases, and diabetes mellitus) were assigned a score, with higher scores given to more severe diseases.^{18,19} We used the first-time diagnosis of a Charlson disease between 1977 (the year of implementation of the DNPR) and the best-estimate date. We had access to all DNPR data for DACOBAN patients, which enables individual linkage for studies comprising other comorbidities than those found in the Charlson Comorbidity Index, as well as surgical procedures.

Vital status

We had complete follow-up information for the vital status of all 39,292 patients except one. On the latest status date (September 27, 2012), 14,375 (36.6%) patients were alive, eleven (0.03%) had disappeared, 192 (0.49%) had emigrated, and the remaining 24,713 (62.9%) were deceased.

Physicians' supplementary variables

For part of the data (Aalborg, 2007–2008; Herlev, 2006–2011; Hvidovre, 2006–2008), covering 8,645 patients with 9,672 bacteremic episodes (19.4%), physicians at the clinical microbiology departments prospectively recorded clinical data in an electronic database that is linked to the DACOBAN database. This enabled the retrieval of clinical data, such as possible focus of infection, empiric and final antibiotic treatment, and intravascular catheterization. These data represent routine assessments based on clinical data and information from positive microbiological specimens other than BCs that are generated by physicians at clinical microbiology departments in close cooperation with physicians at the clinical wards in which the patients were hospitalized. Variables related to antibiotic treatment were incorporated into an algorithm that determined whether the treatment was appropriate.

Research from the database

The population-based data and the high number of patients and bacteremic episodes make the DACOBAN database suitable for surveillance studies.^{5,7} DACOBAN data were recently included in a multinational surveillance study conducted by Laupland et al.⁵ The study included an unprecedentedly high number (ie, 18,430) of incident *Staphylococcus aureus* bacteremic episodes. Incidence rates with detailed

Table 2 Main characteristics of the 49,951 bacteremic episodes, 2000–2011

Characteristic	Number (%)
Age, years	
0–14	1,577 (3.2)
15–64	16,743 (33.5)
65–80	17,577 (35.2)
>80	14,054 (28.1)
Females	23,078 (46.2)
Charlson Comorbidity Index score	
0	13,353 (26.7)
1–2	18,702 (37.4)
>2	17,896 (35.8)
Specialty ^a	
Medical	24,116 (66.0)
Surgical	9,417 (25.8)
Pediatric	1,149 (3.2)
Unknown	1,848 (5.1) ^b
Clinical department ^c	
Bed unit	32,298 (88.4)
Intensive care unit	2,743 (7.5)
Emergency room	804 (2.2)
Ambulatory	602 (1.7)
General practitioner ^c	12 (0.0)
Psychiatric	28 (0.1)
Unknown	43 (0.1)
Acquisition of bacteremia	
Community	20,218 (40.5)
Health care-related	12,080 (24.2)
Nosocomial	17,479 (35.0)
Unknown	174 (0.4)
Group of microorganisms	
<i>Escherichia coli</i>	14,045 (28.1)
<i>Enterobacter</i> spp.	971 (1.9)
<i>Klebsiella</i> spp.	3,323 (6.7)
Other Enterobacteriaceae	2,038 (4.1)
<i>Pseudomonas aeruginosa</i>	1,340 (2.7)
Anaerobic Gram-negative bacteria	1,143 (2.3)
Other Gram-negative bacteria	1,357 (2.7)
<i>Staphylococcus aureus</i>	6,238 (12.5)
Coagulase-negative staphylococci	1,296 (2.6)
<i>Streptococcus pneumoniae</i>	4,080 (8.2)
Hemolytic streptococci	1,754 (3.5)
Enterococci	2,433 (4.9)
Other Gram-positive bacteria	2,417 (4.8)
Gram-positive rods	1,057 (2.1)
Fungi	1,745 (3.5)
Polymicrobial	4,298 (8.6)
Unknown ^d	416 (0.8)

Notes: ^aWhen the blood culture was drawn; only covers the 36,530 bacteremic episodes from 2000 through 2008 because 2009–2011 data have not yet been mapped; ^b1,705 of these (92.3%) were from intensive care units; ^cthe general practitioner does not represent a clinical department, but this was recorded for only 16 of 49,951 bacteremic episodes (0.03%), indicating that virtually all bacteremia patients were hospitalized; ^dmainly due to lack of speciation.

information on regional differences were reported separately for community-acquired and nosocomial bacteremias and methicillin-resistant and methicillin-susceptible episodes from developed countries on three continents during a 9-year period. Another cohort study of enterococci based on data

from DACOBAN revealed some clinically relevant findings on infective endocarditis in 25% of adult patients with *Enterococcus faecalis* bacteremia.⁷ We also found that only 17.7% of patients with *E. faecalis* and 7.4% with *E. faecium* bacteremia received appropriate antimicrobial therapy within the first day after admission.

In a study using the physicians' supplementary variables as the gold standard, we assessed the validity of computer-derived algorithms for contamination versus bacteremic episodes, and among episodes of bacteremia, their acquisition (ie, community, health care-related, or nosocomial) and whether they were monomicrobial or polymicrobial.¹² The results showed high validity for contamination versus bacteremia and for monomicrobial versus polymicrobial bacteremia, but they were less reliable for acquisition.

Koch et al used the unique civil registration number to link DACOBAN data to socioeconomic variables maintained by Statistics Denmark, generating the first bacteremia study showing that low income, low level of education, and low social status were all strong predictors of higher 30-day mortality.²⁰ The same authors matched 4,117 community-acquired bacteremia patients by sex, age, and residency to 41,170 population controls to assess socioeconomic status as a risk factor for bacteremia.²¹ Low education and low income rendered up to a 70% increased risk of bacteremia, even after adjusting for preexisting chronic diseases and drug and alcohol abuse.

Part of the DACOBAN data overlap the North Denmark Bacteremia Research Database, which is a well-established research database with prospectively derived data (eg, focus on infection and antibiotic treatment) that has been the source of roughly 60 publications.⁹ Linkage to this database enables studies that supply clinical data and further validate the retrospective data of the DACOBAN database.

Strengths and weaknesses

The main strengths of the DACOBAN database are its catchment area of well-defined geographic regions with valid population statistics, the high number of patients, the ability to distinguish between incident and nonincident bacteremic episodes due to the patients' longitudinal data, the possibility of complete follow-up for both short-term and long-term mortality, and the flexibility of linking to other administrative registries or research databases. Because patients are recruited from a well-defined geographic/demographic region, the DACOBAN database fulfills one prerequisite for participating in the multinational bacteremia collaborative network. The estimated coverage of 88% almost fulfills the

Table 3 Main variables

Main group	Variable	Description/comments
Basic characteristics	Civil registration number	Unique personal identification number given to all Danish residents
	DACOBAN region	Aalborg, Herlev, or Hvidovre
	Retrieval date of BC	
	Receipt date of BC at department of clinical microbiology	
	Best-estimate date	Retrieval date; if this was missing, receipt date (never missing)
	Date of admission	For the bacteremic episode
	Date of discharge	For the bacteremic episode
	Clinical specialty that retrieved the BC	Medical, surgical, pediatric, or unknown
Microbiology	Clinical department that retrieved the BC	Bed unit, intensive care unit, emergency room, ambulatory, general practitioner ³ , psychiatry, or unknown
	Number of bacteremic episodes for each patient	Numbered chronologically
	Acquisition of bacteremia	Community, health care-related, nosocomial
	Microorganism	Each species is given a unique number
Comorbidity	Antibiotic-resistance data	As criteria differ between DACOBAN regions data should be interpreted with caution
	Charlson Comorbidity Index points	
Vital status	Date of earliest diagnosis of Charlson comorbid condition	As from 1977
	Status	Alive, disappeared, emigrated, or deceased
Physicians' supplementary variables	Status date	Updated September 27, 2012
	Clinical department at first notification	
	Clinical department that retrieved the BC	
	Foreign bodies	
	Allergy	
	Contamination or bacteremic episode	
	Acquisition of bacteremia	Community, health care-related, nosocomial
	Focus of infection	
	Immunosuppression	
	Comorbidity	
	Surgery performed	Yes versus no
	Catheter treatment(s)	
	Antibiotic treatment, first notification	
	Antibiotic recommendation, first notification	
Antibiotic treatment, second notification		
Antibiotic recommendation, second notification		
Antibiotic treatment appropriate		

Note: ³The general practitioner does not represent a clinical department, but this was recorded only for 16 of 49,951 bacteremic episodes (0.03%), indicating that virtually all bacteremia patients were hospitalized.

Abbreviations: DACOBAN, Danish Collaborative Bacteraemia Network; BC, blood culture.

other prerequisite stating that $\geq 90\%$ of positive BCs have to be identified. In general, we think that the population-based principles are fulfilled, but unpublished data indicate that for the lower catchment in the Capital Region, caution is warranted in interpreting nosocomial bacteremic episodes among 0- to 40-year-old patients from this region. Such episodes comprised 2,989 of the 49,951 DACOBAN database episodes (6%).

The high number of patients enables precise statistical measures, and is advantageous for the study of rare microorganisms, which are often difficult to find in sufficient numbers among data from single clinical wards. Thus far, the DACOBAN database covers 12 years, an appropriate time

span for studying longitudinal aspects, such as the recurrence of bacteremic episodes²² or the incidence of microorganisms related to changes in laboratory procedures.¹⁷

Most prognostic bacteremia studies report only in-hospital mortality, mainly because mortality after discharge is difficult to obtain in most non-Scandinavian countries. In-hospital mortality is heavily influenced by the length of admission. The DACOBAN database enables time-derived follow-up periods, such as 30-day or 365-day mortality. The Danish Civil Registration System is virtually 100% accurate, which also applies to the date of death.⁶

The civil registration number facilitates linkage to other registries, including the retrieval of matched controls from the

background population using incidence-density sampling.²³ It also enables the retrieval of supplementary data from clinical microbiology departments, such as information on negative BCs²⁴ or other specimen types. Further examples include socioeconomic data as described earlier, redemptions of prescribed drugs from pharmacies,²⁵ and the more than 50 nationwide clinical databases that cover specific disease entities, interventions, or activities.²⁶

The lack of clinical and paraclinical data related to the acute illness encountered in bacteremia patients constitutes the main limitation of the DACOBAN database. Clinical data, apart from discharge diagnoses found in the DNPR, are not recorded electronically and are very labor-intensive to obtain. Paraclinical data, however, are recorded electronically in all hospitals. The recent compilation of all paraclinical data into an accessible nationwide electronic registry by actors outside of the DACOBAN group offers new unique opportunities, in contrast to earlier studies in which linking data to paraclinical data from the individual hospital was the only option.^{27,28}

The clinical data in the DACOBAN database mainly relate to chronic diseases exemplified by the Charlson Comorbidity Index, which is commonly used and validated for prognostic purposes.¹⁹ The DNPR is less accurate than the Danish Civil Registration System, and has undergone changes of which the researcher should be aware.⁸ However, the computation of previous comorbid conditions as a summary adjustment measure in prognostic models is sufficient.

The physicians' supplementary variables described earlier yield information on important clinical aspects related to the bacteremic episode, such as the possible focus of infection, the appropriateness of the antibiotic treatment, and whether the patient was intravascularly catheterized. However, care is warranted in interpreting these data, as they represent numerous physicians' routine assessments, with no evaluation of interobserver agreement or the use of formally specified criteria.¹² Despite the fact that the supplementary variables have been included for only a limited period of time, the source data are recorded continuously as an integral part of the physicians' documentation of contacts with the patients' clinical teams. With more effective methods for handling data on the patient's clinical state, the possible foci of infection, and clinical decision making, such data could become a valuable part of the DACOBAN database in the future.

Another limitation relates to the possible inaccuracy in determining bacteremic episodes from an array of positive BCs.^{22,29} We partly evaluated the validity of the computer algorithms used for this purpose,¹² but more work is required to assess its robustness, such as in prognostic models.

Data-resource access

Interested collaborators are encouraged to mail the corresponding author, who will forward the request to the DACOBAN steering committee (HCS, MA, JDK, and CØ). Linkage to other registries has to be performed by the DACOBAN group, as the civil registration number will be encrypted prior to data delivery, in accordance with Danish legislation. The DACOBAN database was approved according to the guidelines of the Regional Committee on Health Research Ethics for use of clinical and laboratory data (Danish Data Protection Agency, record 2007-41-0627). Additional permissions from the Danish Data Protection Agency will be required for external collaborators.

Acknowledgments

Contributing members of DACOBAN: Christian Østergaard (Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark), Magnus Arpi (Department of Clinical Microbiology, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark), Kim Oren Gradel (Center for National Clinical Databases – South, Odense University Hospital, Odense, Denmark), Ulrich Stab Jensen (Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark), Sara Thønnings (Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark), Jenny Dahl Knudsen (Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark), Kristoffer Koch (Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark), Mette Pinholt (Department of Clinical Microbiology, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark), Jesper Smit (Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark), Henrik Carl Schønheyder (Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark), Mette Søgaard (Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. *Clin Microbiol Infect.* 2013;19:501–509.
2. Schønheyder HC, Paul M. Placing the burden of bacteraemia in perspective. *Clin Microbiol Infect.* 2013;19:489–491.

3. Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. *Rev Infect Dis.* 1983;5:35–53.
4. Laupland KB, Schönheyder HC, Kennedy KJ, et al. Rationale for and protocol of a multi-national population-based bacteremia surveillance collaborative. *BMC Res Notes.* 2009;2:146.
5. Laupland KB, Lyytikäinen O, Søgaard M, et al. The changing epidemiology of *Staphylococcus aureus* bloodstream infection: a multinational population-based surveillance study. *Clin Microbiol Infect.* 2013;19:465–471.
6. Pedersen CB. The Danish Civil Registration System. *Scand J Public Health.* 2011;39:22–25.
7. Pinholt M, Østergaard C, Arpi M, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. *Clin Microbiol Infect.* 2014;20:145–151.
8. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public Health.* 2011;39:30–33.
9. Schönheyder HC, Søgaard M. Existing data sources for clinical epidemiology: the North Denmark Bacteremia Research Database. *Clin Epidemiol.* 2010;2:171–178.
10. Olsen J, Basso O, Sørensen HT. What is a population-based registry? *Scand J Public Health.* 1999;27:78.
11. Trick WE, Zagorski BM, Tokars JI, et al. Computer algorithms to detect bloodstream infections. *Emerg Infect Dis.* 2004;10:1612–1620.
12. Gradel KO, Knudsen JD, Arpi M, Østergaard C, Schönheyder HC, Søgaard M. Classification of positive blood cultures: computer algorithms versus physicians' assessment – development of tools for surveillance of bloodstream infection prognosis using population-based laboratory databases. *BMC Med Res Methodol.* 2012;12:139.
13. Uslan DZ, Crane SJ, Steckelberg JM, et al. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. *Arch Int Med.* 2007;167:834–839.
14. Skogberg K, Lyytikäinen O, Ollgren J, Nuorti JP, Ruutu P. Population-based burden of bloodstream infections in Finland. *Clin Microbiol Infect.* 2012;18:E170–E176.
15. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control.* 1988;16:128–140.
16. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Int Med.* 2002;137:791–797.
17. Søgaard M, Engebjerg MC, Lundbye-Christensen S, Schönheyder HC. Changes in blood culture methodology have an impact on time trends of bacteraemia: a 26-year regional study. *Epidemiol Infect.* 2011;139:772–776.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40:373–383.
19. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a critical review of available methods. *J Clin Epidemiol.* 2003;56:221–229.
20. Koch K, Nørgaard M, Schönheyder HC, Thomsen RW, Søgaard M. Effects of socioeconomic status on mortality after bacteremia in working-age patients. A Danish population-based cohort study. *PLoS One.* 2013;8:e70082.
21. Koch K, Søgaard M, Nørgaard M, Thomsen RW, Schönheyder HC. Socioeconomic inequalities in risk of hospitalization with community-acquired bacteremia: a Danish population-based case-control study. *Am J Epidemiol.* 2014;179(9):1096–1106.
22. Jensen US, Knudsen JD, Østergaard C, Gradel KO, Frimodt-Møller N, Schönheyder HC. Recurrent bacteraemia: a 10-year regional population-based study of clinical and microbiological risk factors. *J Infect.* 2010;60:191–199.
23. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. III. Design options. *Am J Epidemiol.* 1992;135:1042–1050.
24. Søgaard M, Nørgaard M, Pedersen L, Sørensen HT, Schönheyder HC. Blood culture status and mortality among patients with suspected community-acquired bacteremia: a population-based cohort study. *BMC Infect Dis.* 2011;11:139.
25. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. *Scand J Public Health.* 2011;39:38–41.
26. Green A. Danish clinical databases: an overview. *Scand J Public Health.* 2011;39:68–71.
27. Gradel KO, Thomsen RW, Lundbye-Christensen S, Nielsen H, Schönheyder HC. Baseline C-reactive protein level as a predictor of mortality in bacteraemia patients: a population-based cohort study. *Clin Microbiol Infect.* 2010;17:627–632.
28. Grann AF, Erichsen R, Nielsen AG, Froslev T, Thomsen RW. Existing data sources for clinical epidemiology: the clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. *Clin Epidemiol.* 2011;3:133–138.
29. Roberts FJ. Definition of polymicrobial bacteremia. *Rev Infect Dis.* 1989;11:1029–1030.

Clinical Epidemiology

Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification, systematic

Submit your manuscript here: <http://www.dovepress.com/clinical-epidemiology-journal>

Dovepress

reviews, risk & safety of medical interventions, epidemiology & biostatistical methods, evaluation of guidelines, translational medicine, health policies & economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.